Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer Vaccines01:30

Cancer Vaccines

936
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
936
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

469
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
469

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Updates on the Perioperative Management of Resectable Non-Small Cell Lung Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

The Impact of Neoadjuvant Chemoradiation Therapy on Non-Tumorous Barrett's Dysplasia of the Esophagus: A Multicenter Cohort Study.

Journal of clinical medicine·2026
Same author

Stereotactic Body Radiation Therapy Utilization Trends for Stage I Non-Small Cell Lung Cancer.

Chest·2025
Same author

A Cost-effectiveness Analysis of Adjuvant Alectinib in Patients With Resectable ALK -positive Non-small Cell Lung Cancer in the United States.

American journal of clinical oncology·2025
Same author

CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB-IIIA NSCLC.

JTO clinical and research reports·2025
Same author

A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)·2025
Same journal

Pleuropulmonary Infectious Diseases: Impact of the Diseases and the Scarce Literature.

Thoracic surgery clinics·2026
Same journal

TB or Not TB-Septic or Resect? That Is the Question.

Thoracic surgery clinics·2026
Same journal

Surgery for Pulmonary Aspergillosis.

Thoracic surgery clinics·2026
Same journal

Current Treatment for Mediastinitis.

Thoracic surgery clinics·2026
Same journal

Surgical Management of Pulmonary Mucormycosis.

Thoracic surgery clinics·2026
Same journal

Surgical Management of Pulmonary Hydatid Disease.

Thoracic surgery clinics·2026
查看所有相关文章

相关实验视频

Updated: Jan 10, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K

新辅助免疫疗法新辅助免疫疗法

Jay M Lee1

  • 1Thoracic Oncology Program, Jonsson Comprehensive Cancer Center; Division of Thoracic Surgery, David Geffen School of Medicine, UCLA Health, Los Angeles, CA, USA.

Thoracic surgery clinics
|November 19, 2025
PubMed
概括
此摘要是机器生成的。

免疫检查点抑制剂 (ICI) 单疗法正在研究早期非小细胞肺癌. 结合化疗和ICI (CT-ICI) 显示出优异的病理结果,成为首选的策略.

关键词:
早期阶段 早期阶段免疫检查点抑制抑制免疫治疗是一种免疫疗法.肺癌是一种肺癌.新辅助剂是一种新辅助剂.非小细胞肺癌的肺癌.经期操作性 经期操作性可以切割的可切割.

更多相关视频

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
07:04

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Published on: September 16, 2018

10.7K
Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

23.9K

相关实验视频

Last Updated: Jan 10, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K
Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
07:04

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Published on: September 16, 2018

10.7K
Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

23.9K

科学领域:

  • 在瘤学瘤学.
  • 免疫治疗是一种免疫疗法.
  • 胸部外科手术 胸部外科手术

背景情况:

  • 免疫检查点抑制剂 (ICI) 单疗法目前正在研究早期非小细胞肺癌 (eNSCLC).
  • 新辅助药试验确定了关键的早期反应标志物,如主要病理回归和病理完整反应 (pCR).

研究的目的:

  • 评估eNSCLC中新辅助免疫检查点抑制剂 (ICI) 的疗效和安全性.
  • 为了比较ICI单疗法与联合化疗和ICI (CT-ICI).

主要方法:

  • 对ICI单疗法和CT-ICI的第二阶段新辅助药试验的分析.
  • 评估早期反应标志物,包括主要病理回归,pCR和客观反应率.
  • 考虑监管部门批准所需的长期结果.

主要成果:

  • 与ICI单独治疗相比,CT-ICI显示出更好的病理结果.
  • pCR是一个有价值的早期疗效标志物,但长期生存数据对于FDA批准至关重要.
  • ICI单疗显示出有利的安全性和耐受性.
  • 没有化疗的双重ICI疗法仍在调查中.

结论:

  • 结合CT-ICI是基于优异的病理结果为eNSCLC的首选新辅助策略.
  • 虽然早期反应标记具有信息性,但FDA的最终批准取决于长期无事件或整体存活率.
  • 在eNSCLC中对无化疗的双重ICI疗法需要进一步研究.